Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy

NCT ID: NCT04579822

Last Updated: 2020-10-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a nationwide cohort study to assess maternal and fetal outcomes following vaccination with a quadrivalent influenza vaccine (QIV) during pregnancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Korean National Immunization Program (NIP) first introduced quadrivalent influenza immunization for all pregnant women in the 2020-2021 season. This nationwide cohort study is proposed to assess the risks of adverse maternal and fetal outcomes following vaccination with a quadrivalent influenza vaccine (QIV) during pregnancy. We will use the national health insurance database from the National Health Insurance Service (NHIS) linked with the national immunization program registry data from the Korea Centers for Diseases Control \& Prevention (KCDC).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Related Influenza Virus Vaccine Adverse Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women vaccinated with a QIV

Women aged 20-44 years who had received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.

influenza vaccine

Intervention Type BIOLOGICAL

quadrivalent influenza vaccination in the flu seasons

Pregnant women unvaccinated with a QIV

Women aged 20-44 years who had not received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.

influenza vaccine

Intervention Type BIOLOGICAL

quadrivalent influenza vaccination in the flu seasons

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

influenza vaccine

quadrivalent influenza vaccination in the flu seasons

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women between September 22, 2020, and April 30, 2021.

Exclusion Criteria

* Women aged \<20 or \>45 years
* Pregnancies with a chromosomal abnormality
* Pregnancies with exposure to a known teratogenic medication
Minimum Eligible Age

20 Years

Maximum Eligible Age

44 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Government-wide R&D Fund project for infectious disease research (GFID)

UNKNOWN

Sponsor Role collaborator

Sungkyunkwan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ju-Young Shin

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ju-Young Shin, PhD

Role: PRINCIPAL_INVESTIGATOR

Sungkyunkwan University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yunha Noh, PharmD

Role: CONTACT

+82-31-299-4377

References

Explore related publications, articles, or registry entries linked to this study.

Baum U, Leino T, Gissler M, Kilpi T, Jokinen J. Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified by trimester of vaccination. Vaccine. 2015 Sep 11;33(38):4850-7. doi: 10.1016/j.vaccine.2015.07.061. Epub 2015 Aug 1.

Reference Type BACKGROUND
PMID: 26238723 (View on PubMed)

Macias Saint-Gerons D, Sola Arnau I, De Mucio B, Arevalo-Rodriguez I, Aleman A, Castro JL, Ropero Alvarez AM. Adverse events associated with the use of recommended vaccines during pregnancy: An overview of systematic reviews. Vaccine. 2021 Jul 30;39 Suppl 2:B12-B26. doi: 10.1016/j.vaccine.2020.07.048. Epub 2020 Sep 21.

Reference Type BACKGROUND
PMID: 32972737 (View on PubMed)

Walsh LK, Donelle J, Dodds L, Hawken S, Wilson K, Benchimol EI, Chakraborty P, Guttmann A, Kwong JC, MacDonald NE, Ortiz JR, Sprague AE, Top KA, Walker MC, Wen SW, Fell DB. Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study. BMJ. 2019 Jul 10;366:l4151. doi: 10.1136/bmj.l4151.

Reference Type BACKGROUND
PMID: 31292120 (View on PubMed)

Ludvigsson JF, Strom P, Lundholm C, Cnattingius S, Ekbom A, Ortqvist A, Feltelius N, Granath F, Stephansson O. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. BMJ. 2015 Nov 16;351:h5585. doi: 10.1136/bmj.h5585.

Reference Type BACKGROUND
PMID: 26572546 (View on PubMed)

Hviid A, Svanstrom H, Molgaard-Nielsen D, Lambach P. Association Between Pandemic Influenza A(H1N1) Vaccination in Pregnancy and Early Childhood Morbidity in Offspring. JAMA Pediatr. 2017 Mar 1;171(3):239-248. doi: 10.1001/jamapediatrics.2016.4023.

Reference Type BACKGROUND
PMID: 27893898 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SKKU-2020-FP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Influenza Vaccine in Pregnant Women
NCT00905125 COMPLETED PHASE2
H1N1 Vaccine in Pregnant Women
NCT00963430 COMPLETED PHASE2
Opting In vs Opting Out
NCT01233804 COMPLETED NA
Novartis H1N1 Vaccine in Pregnant Women
NCT00992719 COMPLETED PHASE2
Afluria Pregnancy Registry
NCT03442582 COMPLETED